Dyadic International (NASDAQ:DYAI – Get Free Report) and Genenta Science (NASDAQ:GNTA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Risk and Volatility
Dyadic International has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Profitability
This table compares Dyadic International and Genenta Science’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyadic International | -188.09% | -149.16% | -59.81% |
| Genenta Science | N/A | N/A | N/A |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyadic International | $2.90 million | 19.49 | -$6.80 million | ($0.23) | -8.30 |
| Genenta Science | N/A | N/A | -$12.60 million | N/A | N/A |
Dyadic International has higher revenue and earnings than Genenta Science.
Insider & Institutional Ownership
28.0% of Dyadic International shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 28.8% of Dyadic International shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Dyadic International and Genenta Science, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyadic International | 0 | 0 | 1 | 0 | 3.00 |
| Genenta Science | 0 | 0 | 1 | 0 | 3.00 |
Dyadic International presently has a consensus target price of $6.00, indicating a potential upside of 214.14%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 421.92%. Given Genenta Science’s higher probable upside, analysts clearly believe Genenta Science is more favorable than Dyadic International.
Summary
Genenta Science beats Dyadic International on 6 of the 9 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
About Genenta Science
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
